Last reviewed · How we verify
Blood component B
Blood component B, marketed by Università degli Studi di Ferrara, holds a niche position in the pharmaceutical market. The key composition patent for the drug is set to expire in 2028, providing a clear timeline for potential generic competition. The lack of detailed revenue and trial data poses a significant challenge in assessing the drug's current market performance and future prospects.
At a glance
| Generic name | Blood component B |
|---|---|
| Sponsor | Università degli Studi di Ferrara |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation (PHASE1)
- MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence (NA)
- Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (PHASE2, PHASE3)
- Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis (PHASE3)
- Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (PHASE2)
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |